Review of efficacy of baricitinib in the treatment of alopecia areata
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20231172Keywords:
AA, Baricitinib, JAK inhibitorsAbstract
Alopecia areata (AA) is a long-term autoimmune condition characterized by patchy, non-scarring hair loss. It involves an autoimmune inflammatory process that gives immunity privilege to some hair follicles, while subsequent inflammatory attacks target previously normal hair follicles. One of the most important discoveries in the pathogenesis of this disease is the Janus kinase (JAK)-signal transducer and activator of the transcription (STAT) pathway. Now that a greater understanding of the immunological processes contributing to the pathogenesis has been gained, current trials’ focus was on managing the immunological reaction involved in this disease. Baricitinib is a new first-generation JAK inhibitor that has been studied in multiple trials. This study's objectives were to review existing research and summarize information on the use of Baricitinib to treat AA. The Medline database was searched for relevant published research papers using variations of the following keywords: “AA,” “Baricitinib,” and “JAK inhibitors.” The search covered studies published from 2010–2022. Our findings showed that baricitinib’s use for severe AA in multiple studies generally led to improvement of patients’ conditions with minimal side effects.
Metrics
References
Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol. 2012;83:1136-45.
Kisseleva T, Bhattacharya S, Braunstein J, Schindler C. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285:1-24.
Xing L, Dai Z, Jabbari A. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043-9.
Nguyen B, Hu JK, Tosti A. Eyebrow and eyelash alopecia: A Clinical Review. Am J Clin Dermato. 2022;1.
Alharthi S, Turkmani M, Al Jasser M. Acne exacerbation after tofacitinib treatment for alopecia areata. Dermatol Rep. 2022;1-2.
Crowley EL, Fine SC, Katipunan KK, Gooderham MJ. The use of Janus kinase inhibitors in alopecia areata: a review of the literature. J Cutan Med Surg. 2019;23:289-97.
Pourang A, Mesinkovska NA. New and emerging therapies for alopecia areata. Drugs. 2020;80:635-46.
Garcia-Melendo C, Cubiró X, Puig L. Janus kinase inhibitors in dermatology: part 1-general considerations and applications in vitiligo and alopecia areata. Actas Dermo-Sifiliográficas (English Edition). 2021;112:503-15.
Strazzulla LC, Wang EHC, Avila L. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78:1-12.
Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76:745-53.
Walker J, Ahern M, Coleman M. Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:992-9.
Jabbari A, Dai Z, Xing L. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2:351-5.
Mackay-Wiggan J, Jabbari A, Nguyen N. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1.
Petukhova L, Duvic M, Hordinsky M. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466:113-7.
Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata. Lancet. 2019;393(10169):318-9.
de Oliveira AB, Alpalhao M, Filipe P, Maia‐Silva J. The role of Janus kinase inhibitors in the treatment of alopecia areata: a systematic review. Dermatol Ther. 2019;32:e13053.
Wang Y, Liu T, Li S. Efficacy and safety of baricitinib in patients with refractory alopecia areata. Dermatol Ther. 2022;35.
Phan K, Sebaratnam D. JAK inhibitors for alopecia areata: a systematic review and meta‐analysis. J Eur Acad Dermatol Venereol. 2019;33:850-6.
Dillon K-AL. A Comprehensive literature review of JAK Inhibitors in treatment of alopecia areata. Clin Cosmet Investig Dermatol. 2021;14:691.
Meah N, Wall D, York K. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83:123-30.
Kranseler JS, Sidbury R. Alopecia areata: Update on management. Indian J Pediatr Dermatol. 2017;18:261.
Klein B, Treudler R, Simon JC. JAK‐inhibitors in dermatology–small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. J Deutschen Dermatologischen Gesellschaft. 2022;20:19-24.
Mishra P, Sinha S, Vihan S. Baricitinib: first systemic oral drug for alopecia therapy. J Pharm Care. 2022;12.
King B, Ohyama M, Kwon O. Two phase 3 trials of Baricitinib for alopecia areata. N Engl J Med. 2022;386:1687-99.
Mahmoud AM. Effectiveness and safety of baricitinib in patients with alopecia areata: a systematic review and Meta-analysis of randomized controlled trials. Curr Med Res Opin. 2022;1-9.
Simpson EL, Bieber T, Guttman-Yassky E. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335-48.
Senna MM, Kwon O, Piraccini BM. 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss. J Am Academy Dermatol. 2022;87:AB144.
Teixeira FV, Vilela EG, Damião AOMC. Ulcerative colitis-treatment with biologicals. Revista da Associação Médica Brasileira. 2019;65:547-53.
Tanaka Y, Atsumi T, Amano K. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: subgroup analyses of four multinational phase 3 randomized trials. Mod Rheumatol. 2018;28:583-91.
Le M, Berman-Rosa M, Ghazawi FM. Systematic review on the efficacy and safety of oral Janus kinase inhibitors for the treatment of atopic dermatitis. Front Med. 2021;8.
Seneschal J, Boniface K, Jacquemin C, editors. Alopecia areata: Recent advances and emerging therapies. Ann Dermatologie et de Vénéréologie. 2022;1.
Montilla AM, Gómez-García F, Gómez-Arias PJ. Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther. 2019;9:655-83.
King B, Ko J, Forman S. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85:847-53.
King B, Mostaghimi A, Shimomura Y, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;12.
Mesinkovska NA, Ito T, Senna M. 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials. J Am Acad Dermatol. 2022;87:AB50.
Lintzeri DA, Constantinou A, Hillmann K. Alopecia areata-current understanding and management. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2022;20:59-90.
Zhang J, Qi F, Dong J. Application of baricitinib in dermatology. J Inflammation Res. 2022;15:1935.
Lensing M, Jabbari A. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022;13.
Fukuyama M, Ito T, Ohyama M. Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol. 2022;49:19-36.
Moussa A, Eisman S, Kazmi A. Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients. J Am Acad Dermatol. 2023;1.
Downloads
Published
How to Cite
Issue
Section
